Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS, Pawlotsky JM.

J Infect Dis. 2010 Nov 1;202(9):1309-18. doi: 10.1086/656528.

2.

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ.

Gastroenterology. 2014 May;146(5):1240-8. doi: 10.1053/j.gastro.2014.01.044. Epub 2014 Jan 23. Erratum in: Gastroenterology. 2015 Jan;148(1):263. Lau, George [added].

PMID:
24462735
3.

[A cohort study on the epidemiological characteristics of HBeAg sero-clearance in HBeAg positive chronic hepatitis B patients in Jiangsu province from 2012 to 2014].

Zhu LG, Jiang J, Song C, Zou Y, Xu JF, Liu HJ, Peng H, Hu ZB, Zhu FC, Shen HB, Zhai XJ.

Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Feb 10;38(2):179-184. doi: 10.3760/cma.j.issn.0254-6450.2017.02.009. Chinese.

PMID:
28231662
4.

Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.

Wong GL, Chan HL, Lo AO, Chan HY, Tse CH, Chim AM, Wong VW.

Antivir Ther. 2013;18(8):979-86. doi: 10.3851/IMP2615. Epub 2013 Jun 6.

PMID:
23744529
5.

Treatment of chronic hepatitis B: Evolution over two decades.

Yuen MF, Lai CL.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43. doi: 10.1111/j.1440-1746.2010.06545.x. Review.

PMID:
21199525
6.

[Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].

Lu H, Ma LX, Xu WS, Zhang HY, Yu LJ, Duan HY.

Zhonghua Gan Zang Bing Za Zhi. 2003 Mar;11(3):173-5. Chinese.

PMID:
12681068
7.

A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.

Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z.

Med Sci Monit. 2002 Apr;8(4):CR257-62.

PMID:
11951067
8.

Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.

Dusheiko G.

Liver Int. 2013 Feb;33 Suppl 1:137-50. doi: 10.1111/liv.12078. Review.

PMID:
23286858
9.

Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.

van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HL, Schalm SW, de Man RA.

J Viral Hepat. 2006 Feb;13(2):96-103.

PMID:
16436127
10.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E.

Gastroenterology. 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028. Epub 2013 Dec 22.

PMID:
24368224
11.

[Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].

Zheng Q, Zhu YY, Chen J, Liu YR, You J, Zeng DW, Lin S, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Nov;20(11):801-6. doi: 10.3760/cma.j.issn.1007-3418.2012.11.001. Chinese.

PMID:
23206296
12.

Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.

Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–HBV (REVEAL-HBV) Study Group.

Clin Gastroenterol Hepatol. 2012 May;10(5):527-34.e1-2. doi: 10.1016/j.cgh.2011.12.019. Epub 2011 Dec 16.

PMID:
22178461
13.

Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.

Chen J, Wang Z, Zhou B, Wang Y, Hou J.

Antivir Ther. 2012;17(1):71-9. doi: 10.3851/IMP1925.

PMID:
22267471
14.
15.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.

N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

16.

The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.

Demirören K, Kocamaz H, Doğan Y.

Turk J Gastroenterol. 2015 Jan;26(1):36-41. doi: 10.5152/tjg.2015.4636.

17.

[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].

Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.

Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):564-8. Chinese.

PMID:
19719911
18.

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV.

Hepatology. 2008 Sep;48(3):759-69. doi: 10.1002/hep.22419.

PMID:
18697210
19.

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.

J Hepatol. 2007 Sep;47(3):366-72. Epub 2007 May 24.

PMID:
17561304
20.

Telbivudine versus lamivudine in patients with chronic hepatitis B.

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group.

N Engl J Med. 2007 Dec 20;357(25):2576-88.

Supplemental Content

Support Center